Mice were injected intravenously with 200 IU/kg of rFVIII via the tail vein. At the indicated timepoints, blood was collected from anesthetized mice via the retro-orbital plexus in one-tenth volume of 3.2% sodium citrate. Mice were sampled a maximum of 3 times from alternating retro-orbital plexes. Plasma was isolated by centrifugation. FVIII activity (FVIII:C) was measured using the Chromogenix Coatest SP4 Factor VIII (Diapharma, West Chester Township, OH) chromogenic kit using a standard curve generated from the corresponding rFVIII lot in FVIII-deficient pooled mouse plasma. Values were normalized to a sample collected 5 min after infusion.
FVIII deglycosylation
rFVIII was desialylated and de-N-glycosylated using α2-3,6,8 neuraminidase and PNGase F (New England Biolabs, Ipswich. MA), respectively, both under non-denaturing conditions at 37°C for 18 hours in the manufacturer's recommended buffer; controls were incubated in buffer without enzyme. The glycosidase was removed via dialysis (100 kDa MWCO) in PBS containing 0.5 µM Cu 2+ . Glycan removal was confirmed by lectin binding assay. FVIII:C procoagulant activity and antigenicity was assessed by 1-stage clotting assay and FVIII:Ag ELISA (Affinity Biologicals), respectively.
IFN-γ ELISPOT
rFVIII-induced secretion of IFN-γ were quantified by ELISPOT according to the manufacturers protocol (Mouse IFN gamma ELISPOT Ready-SET-Go!, eBioscience). Splenocytes from naïve or rFVIII-primed mice were aseptically isolated and seeded into ELISPOT plate (EMD Millipore) at 5 x 10 5 cells/well in RPMI 1640 media supplemented with 10% FBS, 1% penicillin/streptomycin, 50 µM β-mercaptoethanol. Cells were then stimulated for 48 hours with different rFVIII conditions at 37°C . Total number of IFN-γ-secreting cells were calculated using an automated ELISpot counter (Cellular Technology). FVIII-specific spots were calculated by subtracting unstimulated wells.
In-vitro FVIII binding and uptake analyses
Splenocytes isolated from FVIII naïve hemophilia A mice were incubated with 0-1 µg/mL rFVIII or deglycosylated rFVIII at 4°C for 1 hour. Cells were stained using a FITC-conjugated polyclonal sheep anti-FVIII antibody (Affinity Biologicals), and anti-CD11c antibody (clone: N418, Invitrogen, Carlsbad, CA); the data were acquired on a MACSQuant Analyzer 10 (Miltenyi Biotec, Bergisch Gladbach, Germany) and analyzed using FlowJo software (Tree Star, Ashland, OR).
Human samples
Plasma was isolated by centrifugation of whole blood collected from healthy male and female volunteers (age 22-65). All participants gave informed consent, and this study was approved by the Research Ethics Board of Queen's University, Kingston, Canada. 
